Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 16/12/2021 In-vivo-Gentherapien wie Zolgensma und Ex-vivo-Gentherapien wie CAR-T-Zellen.

    Advanced therapy medicinal products: gene and cell therapies

    Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advanced-therapy-medicinal-products-gene-and-cell-therapies
  • Dossier - 18/06/2012 import_03860_de.jpg

    Biobanks treasure chests for biomedical research

    The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research
  • Press release - 18/11/2021

    Overcoming resistance to treatment for breast, bowel, and pancreatic cancer

    As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
  • Press release - 13/06/2024

    BioRegio STERN receives 2024 award for best ZIM innovation network

    BioRegio STERN Management GmbH was today presented with an award at the Innovation Day for SMEs held by Germany’s Federal Ministry for Economic Affairs and Climate Action. Its “biohymed” project was named the year’s best innovation network under the Central Innovation Programme for SMEs (ZIM).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bioregio-stern-receives-2024-award-best-zim-innovation-network
  • Press release - 22/07/2025

    Colorectal cancer in type 2 diabetes: An insightful look into the microenvironment of tumors

    Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-type-2-diabetes-insightful-look-microenvironment-tumors
  • Press release - 01/08/2025

    In science we trust? Six takeaways from a Science and Society conference

    EMBL's latest Science and Society conference brought together researchers, ethicists, communicators, policy professionals, and more to discuss the thorny question of trust in science.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/science-we-trust-six-takeaways-science-and-society-conference
  • Press release - 28/10/2025

    AI solutions from the DKFZ set new standards in medical image processing

    Researchers at the German Cancer Research Center (DKFZ) have achieved outstanding success at this year's world-leading forum for medical image processing and computer-assisted intervention. Two DKFZ departments competed in eight international AI competitions – and won seven of them. The successes cover key areas of oncology – from early detection and diagnosis to therapy support and follow-up care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-solutions-dkfz-set-new-standards-medical-image-processing
  • Press release - 04/05/2026

    How personalised is healthcare?

    This year’s Health Congress at Furtwangen University (HFU) focused on the timely topic of personalised healthcare. With the theme “Health for EVERYONE! – Successful Strategies Through personalised Healthcare,” HFU hosted the event for the 15th time in collaboration with the Black Forest-Baar Health Network, the Furtwangen University Support Association PRO HFU e.V., and the City of Furtwangen.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-personalised-healthcare
  • Workplace of the future - 10/08/2021 Prototype image of a body support system that fixes a person at the abdomen and hips

    Intelligent body support system for surgery staff

    Operating room staff often spend hours in strenuous postures, which has a significant impact on concentration and quality of work. While operating room equipment is increasingly networked, state-of-the-art medical technology, conditions for operating room staff trail way behind. The start-up company Hellstern medical offers an effective solution for serious pain, fatigue and incorrect interventions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-body-support-system-surgery-staff
  • New edition - 24/05/2019 Magnetic resonance image of brain metastases.

    Tumour metastasis

    Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
  • Press release - 01/09/2022

    Personalised antibiotic treatment strategies for tuberculosis patients

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
  • Press release - 01/12/2022

    Development of the immune system before and after birth

    The newborn's immune system is suddenly confronted with microorganisms, food and numerous environmental influences at birth. How do the baby's immune cells prepare for this moment during pregnancy and birth? How do external influences shape the immune system immediately after birth? And what influence does an event like a premature birth have?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/development-immune-system-and-after-birth
  • Press release - 16/06/2023

    What determines whether breast cancer cells can form metastases?

    In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancer

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-determines-whether-breast-cancer-cells-can-form-metastases
  • Press release - 08/09/2026

    Heisenberg Professorship for Aurélie Ernst

    With funding from the German Research Foundation’s (DFG) Heisenberg Program, DKFZ researcher Aurélie Ernst aims to investigate how massive changes in the genome contribute to the development of cancer. Her research focuses on a phenomenon known as chromothripsis - a catastrophic event in the genome in which chromosomes break apart and are reassembled incorrectly.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heisenberg-professorship-aurelie-ernst
  • Press release - 09/11/2022

    New Molecular Microscopy Uncovers how Breast Cancer Spreads

    Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
  • Press release - 26/05/2026

    Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

    Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis
  • Press release - 12/03/2025

    Hepatic stellate cells control liver function and regeneration

    Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions have hardly been studied to date. Researchers from the German Cancer Research Center, the Mannheim Medical Faculty and Columbia University have now published that hepatic stellate cells control liver metabolism as well as liver regeneration and size. The results of the study could contribute to new therapeutic approaches for liver diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hepatic-stellate-cells-control-liver-function-and-regeneration
  • Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 A comic-style illustration of a green sleeping sickness pathogen in blue tissue, with four surface proteins shown in grey, magnified as if under a magnifying glass, to which a green antibody binds.

    Reaching the unreachable: new approaches to challenging drug targets

    Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
  • Press release - 06/02/2023

    Fewer side effects thanks to personalised medicine

    Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
  • Press release - 16/07/2026

    New Findings on Acute Leukemias: Specific Mutations Provide Targets for More Targeted Therapies

    Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-acute-leukemias-specific-mutations-provide-targets-more-targeted-therapies
  • Press release - 22/07/2026

    The Individual Genetic Background Shapes the Evolution of Cancer

    Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/individual-genetic-background-shapes-evolution-cancer
  • Press release - 31/05/2024

    Heidelberg University successful with six bids for collaborative research

    In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-successful-six-bids-collaborative-research
  • Press release - 20/12/2022

    Rapid Evolution of Spermatogenesis

    Heidelberg scientists decode the genetic foundations of rapid testicle evolution in mammals and humans. Evolutionary pressure across male mammals to guarantee the procreation of their own offspring led to a rapid evolution of the testicle.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rapid-evolution-spermatogenesis
  • Press release - 28/01/2021

    Carl Zeiss Foundation funds Interdisciplinary practice Study at Heidelberg University with the sum of approximately of 4.5 Million Euros

    Can interconnected digital assistance systems enhance the quality of life of people in older age? Scientists in an interdisciplinary research project at Heidelberg University are exploring this question in a representative practice study. The participating researchers want to investigate how well these technical aids can be used and what benefit they achieve.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-foundation-funds-interdisciplinary-practice-study-heidelberg-university-sum-approximately-45-million-euros
  • Press release - 17/01/2023

    Endogenous molecule protects from life-threatening complications after stem-cell transplantation

    Acute Graft-versus-host disease (GvHD) is a life-threatening complication after leukemia treatment with allogeneic stem cell transplantation i.e. the transplantation of cells from another person. GvHD occurs when the transplanted immune cells are overly active and damage the receiving patient's healthy tissue. Researchers found that an endogenous molecule can mitigate this misdirected immune response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/koerpereigenes-molekuel-schuetzt-vor-lebensbedrohlichen-komplikationen-nach-stammzelltransplantation

Page 6 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search